软组织肉瘤的个性化药物治疗方案

IF 1 Q4 PHARMACOLOGY & PHARMACY
S. Arifi
{"title":"软组织肉瘤的个性化药物治疗方案","authors":"S. Arifi","doi":"10.1080/23808993.2022.2038562","DOIUrl":null,"url":null,"abstract":"ABSTRACT Introduction Soft tissue sarcomas (STS) are a rare and heterogeneous group of tumors. The role of molecular testing to inform diagnosis, disease prognosis, and therapy has become critical to optimal treatment. Areas covered This review reports updated data on precision therapy in patients with STS, particularly those of immediate utility in clinical practice. Expert opinion There is a high unmet need for effective systemic therapy for patients with STS. In the era of precision medicine, doxorubicin-based chemotherapy is still the standard of care in first-line treatment for the majority of histologic subtypes with a median overall survival of only 20 months. Precision therapy for STS has only been partially effective. A new wave of targeted therapeutic agents has been approved with preferential benefit in subgroups of patients. Immunotherapy is now undergoing clinical trials. There is a heterogeneity in the benefit of immune checkpoint inhibitors across subtypes. Strategies targeted to antigen bearing sarcomas including vaccine and adoptive T-cell have yielded promising results in selected histotypes.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"7 1","pages":"17 - 28"},"PeriodicalIF":1.0000,"publicationDate":"2022-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Personalised pharmacotherapy options for soft tissue sarcomas\",\"authors\":\"S. Arifi\",\"doi\":\"10.1080/23808993.2022.2038562\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACT Introduction Soft tissue sarcomas (STS) are a rare and heterogeneous group of tumors. The role of molecular testing to inform diagnosis, disease prognosis, and therapy has become critical to optimal treatment. Areas covered This review reports updated data on precision therapy in patients with STS, particularly those of immediate utility in clinical practice. Expert opinion There is a high unmet need for effective systemic therapy for patients with STS. In the era of precision medicine, doxorubicin-based chemotherapy is still the standard of care in first-line treatment for the majority of histologic subtypes with a median overall survival of only 20 months. Precision therapy for STS has only been partially effective. A new wave of targeted therapeutic agents has been approved with preferential benefit in subgroups of patients. Immunotherapy is now undergoing clinical trials. There is a heterogeneity in the benefit of immune checkpoint inhibitors across subtypes. Strategies targeted to antigen bearing sarcomas including vaccine and adoptive T-cell have yielded promising results in selected histotypes.\",\"PeriodicalId\":12124,\"journal\":{\"name\":\"Expert Review of Precision Medicine and Drug Development\",\"volume\":\"7 1\",\"pages\":\"17 - 28\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2022-01-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Precision Medicine and Drug Development\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/23808993.2022.2038562\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Precision Medicine and Drug Development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23808993.2022.2038562","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

摘要简介软组织肉瘤是一类罕见的异质性肿瘤。分子检测在诊断、疾病预后和治疗中的作用已成为最佳治疗的关键。本综述报告了STS患者精确治疗的最新数据,特别是那些在临床实践中立即有用的数据。专家意见STS患者对有效系统治疗的需求很高,但尚未得到满足。在精准医学时代,基于阿霉素的化疗仍然是大多数组织学亚型的一线治疗标准,中位总生存期仅为20个月。STS的精确治疗仅部分有效。新一波靶向治疗剂已被批准,在患者亚组中具有优先益处。免疫疗法目前正在进行临床试验。免疫检查点抑制剂在不同亚型中的益处存在异质性。针对携带抗原的肉瘤的策略,包括疫苗和过继性T细胞,在选定的组织类型中产生了有希望的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Personalised pharmacotherapy options for soft tissue sarcomas
ABSTRACT Introduction Soft tissue sarcomas (STS) are a rare and heterogeneous group of tumors. The role of molecular testing to inform diagnosis, disease prognosis, and therapy has become critical to optimal treatment. Areas covered This review reports updated data on precision therapy in patients with STS, particularly those of immediate utility in clinical practice. Expert opinion There is a high unmet need for effective systemic therapy for patients with STS. In the era of precision medicine, doxorubicin-based chemotherapy is still the standard of care in first-line treatment for the majority of histologic subtypes with a median overall survival of only 20 months. Precision therapy for STS has only been partially effective. A new wave of targeted therapeutic agents has been approved with preferential benefit in subgroups of patients. Immunotherapy is now undergoing clinical trials. There is a heterogeneity in the benefit of immune checkpoint inhibitors across subtypes. Strategies targeted to antigen bearing sarcomas including vaccine and adoptive T-cell have yielded promising results in selected histotypes.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.30
自引率
0.00%
发文量
9
期刊介绍: Expert Review of Precision Medicine and Drug Development publishes primarily review articles covering the development and clinical application of medicine to be used in a personalized therapy setting; in addition, the journal also publishes original research and commentary-style articles. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this. Clinical trials and case studies within personalized therapy and drug development. Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment. Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies. Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信